Form 4: Adaptive Biotechnologies Director Katey Einterz Owen Reports Stock and Option Transactions
SEC Form 4 Filing
Director Katey Einterz Owen of Adaptive Biotechnologies Corp reports acquisition of common stock and stock options.
Summary
- On March 4, 2024, Katey Einterz Owen, a director of Adaptive Biotechnologies Corp, acquired 31,328 shares of common stock.
- On the same date, she disposed of 57,235 shares of common stock.
- Following these transactions, Owen directly owns 57,235 shares of common stock.
- Owen also acquired options to purchase 48,044 shares of common stock at an exercise price of $3.99, exercisable in monthly installments over one year from March 4, 2024.
- These options expire on March 4, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 03/04/2024 | Date of stock and option transactions |
| 03/04/2024 | Option vesting start date |
| 03/04/2034 | Option expiration date |
| 03/06/2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.